Literature DB >> 29873180

Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).

Hui Lin Cheng1, Alex Molassiotis1.   

Abstract

AIM: To validate and compare the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx) for measuring chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients.
METHODS: Patients were assessed with the EORTC QLQ-CIPN20, FACT/GOG-Ntx, National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) and World Health Organization criterion of CIPN (WHO-CIPN) from baseline up to 10 assessment points. Internal consistency reliability, convergent validity, discriminant validity and responsiveness of the EORTC QLQ-CIPN20 and FACT/GOG-Ntx were evaluated, respectively. Correlation and regression analysis were used to examine the relationships between these two scales.
RESULTS: Internal reliability coefficients for both scales were above 0.80 across all assessment points. Moderate correlations of the two scales were found with WHO-CIPN (rs  = 0.40-0.44; rs  = -0.42 to -0.46, all P < 0.05) and NCI-CTCAE (rs  = 0.46-0.57; rs  = -0.44 to -0.55, all P < 0.01) at most assessment points. Older patients reported significantly more CIPN symptoms than younger counterparts did (P < 0.05). The hypothesized factor structures of both scales were not confirmed (χ2/df = 3.70-7.01; χ2/df = 2.14-10.43, all P < 0.001). Both scales demonstrated responsiveness with small-to-moderate effect size (r = 0.09-0.46, r = 0.11-0.35). The two scales were highly correlated and were predicted by all domains of each other at specific assessment points (R2  = 0.62-0.87; R2  = 0.76-0.85; respectively, all P < 0.001).
CONCLUSION: The Chinese version of the EORTC QLQ-CIPN20 and FACT/GOG-Ntx demonstrated acceptable reliability, validity and responsiveness and was found comparable in measuring CIPN among Chinese cancer patients at specific assessment points.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Chinese; EORTC QLQ-CIPN20; FACT/GOG-Ntx; chemotherapy-induced peripheral neuropathy; psychometrics

Mesh:

Substances:

Year:  2018        PMID: 29873180     DOI: 10.1111/ajco.13000

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  5 in total

1.  Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale.

Authors:  Karen Kaiser; Madison Lyleroehr; Sara Shaunfield; Leilani Lacson; Maria Corona; Sheetal Kircher; Malin Nittve; David Cella
Journal:  World J Gastrointest Oncol       Date:  2020-02-15

2.  Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time.

Authors:  Mian Wang; Hui Lin Cheng; Violeta Lopez; Raghav Sundar; Janelle Yorke; Alex Molassiotis
Journal:  BMC Cancer       Date:  2019-11-27       Impact factor: 4.430

3.  Validation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity Questionnaire for the Latin American Population.

Authors:  Ivana Leao Ribeiro; Luz Alejandra Lorca; Rodrigo Cuevas-Cid; Snehil Dixit; Nicolás Yáñez-Benavides; Francisco Ortega-Gonzalez
Journal:  Int J Breast Cancer       Date:  2022-09-10

Review 4.  Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.

Authors:  Tiffany Li; Susanna B Park; Eva Battaglini; Madeleine T King; Matthew C Kiernan; David Goldstein; Claudia Rutherford
Journal:  Qual Life Res       Date:  2022-05-21       Impact factor: 3.440

5.  Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant or Neo-Adjuvant Chemotherapy.

Authors:  Hui Lin Cheng; Alex Molassiotis; Anthony Kwun To Leung; Kam Hung Wong
Journal:  Breast Care (Basel)       Date:  2020-06-16       Impact factor: 2.268

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.